Corbus Pharmaceuticals Holdings, Inc. Debt Securities, Available-for-sale, Amortized Cost
Corbus Pharmaceuticals Holdings, Inc. (CRBP) had Debt Securities, Available-for-sale, Amortized Cost of $94.67 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $94.67M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $112.71M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $134.83M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $77.00M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost | Debt Securities, Available-for-sale, Amortized Cost as first filed |
|---|---|---|
| 2026-06-30 | $94.67M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $112.71M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $134.83M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $77.00M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $96.59M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $113.91M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $131.83M 10-K · filed 2026-03-09 | |
| 2024-09-30 | $139.73M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $123.72M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $106.33B 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $7.18M 10-K · filed 2025-03-11 | $7.18B 10-K · filed 2024-03-12 |
| 2023-09-30 | $17.49B 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $28.24B 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $36.97M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $42.32M 10-K · filed 2024-03-12 | $42.32M 10-K · filed 2023-03-07 |
| 2022-09-30 | $53.99M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $47.65M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $19.26M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $55.95M 10-K · filed 2023-03-07 | $55.95K 10-K · filed 2022-03-08 |
| 2021-09-30 | $69.75M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $70.38M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $57.43M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |